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Abstract
The aim of this study was to investigate the impact of a physical activity (PA)-focused behavioural intervention
during and after pulmonary rehabilitation (PR) on PA levels (primary aim), health-related outcomes and self-
efficacy (secondary aims) of patients with COPD. Thirty-two patients were randomly assigned to an
experimental group (EG) or control group (CG). The EG received a PA-focused behavioural intervention
during PR (3 months) and follow-up support (3 months). The CG received PR (3 months). Daily PA was
collected: number of steps; time spent in moderate-to-vigorous PA (MVPA), total PA and sedentary
activities (SA). Secondary outcomes comprised exercise capacity, muscle strength, health-related quality of
life (HRQOL) and self-efficacy. Measures were collected at baseline, 3 and 6 months. Compared with the
CG, the EG improved the number of steps (p ¼ 0.006) and time spent in MVPA (p ¼ 0.007), total PA
(p ¼ 0.014) and SA (p ¼ 0.018) at 3 months. Differences were maintained after follow-up support (0.025 
p  0.040), except for SA (p ¼ 0.781). Exercise capacity, muscle strength and HRQOL were increased at 3
and 6 months (p  0.002) with no between-group differences (0.148  p  0.987). No changes were
observed in self-efficacy (p ¼ 0.899). A PA-focused behavioural intervention during and after PR may
improve patients’ PA levels. Further research is warranted to assess the sustainability of the findings.
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Introduction
Patients with chronic obstructive pulmonary disease
(COPD) are markedly inactive during daily life.1 Low
physical activity (PA) levels have been associated
with adverse outcomes, including hospitalisation and
all-cause mortality;2,3 therefore, increasing patients’
PA has become a desirable outcome.4
Pulmonary rehabilitation (PR) is the cornerstone of
COPD management with well-documented effects on
exercise capacity and health-related quality of life
(HRQOL).5 Hence, it would seem the ideal interven-
tion to promote PA behaviours in patients with
COPD.4 However, previous studies assessing the
impact of PR on PA levels have shown that an
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increase in exercise capacity does not necessarily
translate into significant improvements in patients’
PA.6–8 Alternative methods to produce PA behaviour
change within PR are therefore needed.
In the last decade, several PA-focused interven-
tions complementary to PR have been developed.9
Those including self-monitoring using activity moni-
tors, behaviour change approaches and goal setting
showed the most promising results.10,11However, to
date, only a few randomised controlled trials have
studied the effectiveness of these interventions along
with PR in improving patients’ PA.10,12,13
The aim of this randomised controlled trial was to
investigate the impact of a PA-focused behavioural
intervention during and after a PR programme on
PA levels of patients with COPD. Secondary aims
were to evaluate its effects on health-related outcomes
and self-efficacy.
Methods
Study design
This was a randomised controlled trial. Patients were
randomly assigned to receive a PA-focused beha-
vioural intervention during and after PR (experimen-
tal group (EG)) or PR alone (control group (CG)),
using a computer-generated schedule in random
blocks of two. One researcher kept the allocation
sequence in sealed opaque envelopes, drew the envel-
opes and scheduled patients. Patients knew about
the existence of two groups but not the differences
between interventions. Ethical approval was obtained
from the Central Regional Health Administration
(2011-02-28), Hospital Centre (34428) and National
Data Protection Committee (9250/2012). Written
consent was obtained from each participant. The trial
was registered at ClinicalTrials.gov (NCT02122614)
andwas reported according toCONSORT guidelines.14
Participants
Patients were recruited from 3 primary care centres
and a district hospital. Patients were included if they
were 18 years or older, diagnosed with COPD accord-
ing to the Global Initiative for Chronic Obstructive
Lung Disease (GOLD) criteria,15clinically stable in
the last month (i.e., no hospital admissions or exacer-
bations) and able to provide informed consent. Exclu-
sion criteria consisted of the presence of severe
neurologic, musculoskeletal or psychiatric disorders,
unstable cardiovascular disease or severe visual
impairment and participation in PR in the previous
6 months or in regular strenuous exercise.
Intervention
Patients of both groups underwent 12 weeks (3 months)
of PR between April and July 2014. Additionally, the
EG received a PA-focused behavioural intervention
(3 plus 3 months).
Pulmonary rehabilitation
PR consisted of exercise training and psychosocial
support and education sessions. Exercise training was
held 3 times/week (60 minutes/session) by phy-
siotherapists with expertise in the field and comprised
warm-up, aerobic training, resistance training, balance
training and cool-down (as described elsewhere).11
Psychosocial support and education sessions were con-
ducted once a week (90 minutes) by a multidisciplinary
team. Topics included information about COPD,
promotion of healthy lifestyles (PA, nutrition) and
self-management strategies. PR programmes were
conducted at different times to avoid group
contamination.
PA-focused behavioural intervention
The PA-focused behavioural intervention was imple-
mented by one physiotherapist during the PR pro-
gramme (3 months) and continued for 3 months after
its completion. It was specifically designed to achieve
a sustained increase in patients’ PA levels and was
based on the Social Cognitive Theory (SCT),16 which
acknowledges the role of self-efficacy, goal setting and
performance feedback as core elements of behaviour
change. The present intervention incorporated these
concepts using the Health contract technique17,18 and
objective feedback provided by pedometers. The inter-
vention is described in detail below.
In the first psychosocial support and education ses-
sion, participants in the EG were given a piezoelectric
pedometer (Yamax Power Walker EX-510, Yamasa
Tokey Keiki Corporation, Tokyo, Japan) and a log
diary to record daily steps in order to establish their
baseline steps. These pedometers have shown good
accuracy results at slow (absolute percent error (APE)
4.5–9.1%), self-preferred/normal and fast (APE <
3%) speeds, particularly when worn at the front right
or left sides of the waist or inside the front pockets of
the trousers.19 In the following session, participants
received a Health contract,17 that is, a written
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agreement between each patient and the physiothera-
pist. The physiotherapist assisted patients in complet-
ing the Health contract: they had to formulate an
individualised long-term step-count goal to achieve
by the end of the PR programme, based on their base-
line steps and international PA recommendations
(7000–10,000 steps/day),20 and identify potential facil-
itators (e.g., walking with family/friends, planning a
daily schedule). Participants also received a calendar
to register their short-term step-count goals and daily
steps, which were self-monitored with the pedometer.
Short-term goals were defined on a weekly basis and
consisted of the previous short-term goal plus
approximately 800 additional steps (if the goal of the
previous week was met)21 or the previous goal (if it
was notmet). The final aimwas to achieve the long-term
goal. In each psychosocial support and education ses-
sion, the physiotherapist provided individual feedback
on patients’ performance and helped them to define the
next short-term goal (approximately 20–30 minutes/
session). In the last session, the long-term goal was
reassessed. If achieved, participants were praised and
asked to readjust it for the next 3 months. After PR,
patients continued registering their steps in the calen-
dar and received the physiotherapist’s support on a
weekly (in the first month) and fortnightly (in the
second and third months) basis by telephone calls.
Measures
Participants’ characteristics were assessed at baseline.
Outcomemeasures were collected at baseline, 3months
(i.e., post-PR) and 6 months (i.e., after the PA-focused
behavioural intervention).
Participants’ characteristics
Sociodemographic and anthropometric data were
collected using a structured questionnaire and dys-
pnoea using the Modified Medical Research Coun-
cil dyspnoea scale.22 Lung function was assessed
with a portable spirometer (MicroLab 3500, Care-
Fusion, Kent, San Diego, California, USA)23 and
GOLD grades and exacerbation risk groups were
determined.15
Primary outcome measure
Daily PA levels were assessed using activity monitors
GT3Xþ (ActiGraph, Pensacola, Florida, USA), already
validated in COPD.24,25 Participants wore the device
for 4 consecutive weekdays during waking hours
(except when bathing or swimming).26 Data were
downloaded using Actilife v6.10.4 (ActiGraph). A
valid day was defined as 8 h of wearing time.26
Daily PA included the time spent in moderate-to-
vigorous PA (MVPA, 1952–1 counts-per-minute
(CPM)), total PA (100–1 CPM)27 and number of
steps. Time spent in MVPA was calculated consider-
ing the total time (overall MVPA) and the interna-
tionally recommended duration of 30 min of daily
MVPA, either continuous or in blocks of 10 min
(recommended MVPA).28 Time spent in sedentary
activities (SA, 0–99 CPM) was also calculated.27
Secondary outcome measures
Secondary outcomes comprised exercise capacity
(six-minute walk test),29 quadriceps muscle strength
(one repetition maximum),28 HRQOL (St. George’s
Respiratory Questionnaire (SGRQ) – three domains
and global score)30 and self-efficacy (Self-Efficacy
Scale).31 The questionnaires presented good internal
consistency (SGRQ: 0.695  Cronbach’s a  0.877;
Self-Efficacy Scale: Cronbach’s a ¼ 0.696).
Statistical analysis
Sample size was estimated using the primary outcome
measure based on a pilot study.11 It was found that 12
patients with COPD would be required in each group
to provide 80% power (a ¼ 0.05) to detect significant
between-group differences in MVPA (using the effect
size, η2¼ 0.139). However, as PR programmes have a
considerable dropout rate (approximately 30%),32,33
16 patients per group were recruited. Power analyses
were performed using G*Power v3.1.3 (Franz Faul,
Kiel University, Germany).
Baseline characteristics were compared between
groups and between completers and dropouts with
independent t-tests for normally distributed data,
MannWhitney U-tests for ordinal data and w2 tests for
categorical data. For each outcome, a mixed-model
analysis of variance was used to determine the effects
of time and time  group interaction considering a
level of significance of 0.05. Effect sizes were com-
puted using the partial η2 (η2partial), interpreted as:
η2partial  0.01 small, η2partial  0.06 medium and
η2partial  0.14 large effect.34 Observed power was
also calculated. If interaction was significant, a simple
effects analysis was performed using independent
t-tests to assess between-group differences at each
time point. Data were analysed using SPSS v20.0
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(IBM, Armonk, New York, USA) and GraphPad
Prism v5.0 (GraphPad, La Jolla, California, USA).
Results
Participants
Forty patients were screened (Figure 1); however,
eight were excluded for not meeting the inclusion cri-
teria (n¼ 5) or declining to participate (n¼ 3). There-
fore, 32 patients were allocated to the EG (n ¼ 16) or
CG (n ¼ 16). Participants (27 males) had a mean age
of 66.4+ 8.4 years and a forced expiratory volume in
one second of 67.1+ 20.1% predicted. No significant
between-group differences were found in baseline
characteristics (0.121  p  0.855, Table 1).
Twenty-six participants completed the intervention
and post-test assessments and thus were included in
the analysis. Baseline characteristics were not signif-
icantly different between completers and dropouts
(0.143  p  0.817).
Physical activity
Figure 2 and Table 2 present the main PA findings. A
significant time  group interaction was found for
time spent in overall MVPA (p ¼ 0.030, η2partial ¼
0.21, power ¼ 0.89), recommended MVPA (p ¼ 0.012,
η2partial ¼ 0.17, power ¼ 0.78) and total PA (p ¼ 0.047,
η2partial ¼ 0.12, power ¼ 0.59) and for the number
of steps (p ¼ 0.001, η2partial ¼ 0.27, power ¼ 0.96).
Patients in the EG spent significantly more time in
overall MVPA (3 months: EG¼ 57.8+ 32.8 minutes/
day CG ¼ 26.7 + 19.6 minutes/day, p ¼ 0.007;
6 months: EG ¼ 51.6 + 29.4 minutes/day CG ¼
28.0 + 26.0 minutes/day, p ¼ 0.040), recommended
MVPA (3 months: EG ¼ 23.3 + 28.6 minutes/day
CG ¼ 4.3 + 7.3 minutes/day, p ¼ 0.036; 6 months:
EG¼ 20.3+ 24.2 minutes/day CG¼ 3.8+ 7.4 min-
utes/day, p ¼ 0.033) and total PA (3 months:
EG ¼ 279.5 + 74.0 minutes/day CG ¼ 212.0 +
53.9 minutes/day, p ¼ 0.014; 6 months: EG ¼
Figure 1. Flow diagram.
60 Chronic Respiratory Disease 13(1)
269.3 + 61.5 minutes/day CG ¼ 202.9 + 82.5 min-
utes/day, p ¼ 0.029). In addition, the EG walked on
average more 4010.0 steps/day at 3 months (p ¼
0.006) and 3266.7 steps/day at 6 months (p ¼ 0.025)
more than the CG (Figure 2).
A time  group interaction was also found for SA
(p ¼ 0.031, η2partial ¼ 0.14, power ¼ 0.66). At
3 months, the EG spent significantly less time in SA
(EG ¼ 536.4 + 86.6 minutes/day CG ¼ 625.9 +
93.3 minutes/day, p ¼ 0.018). No between-group
differences were found at 6 months (p ¼ 0.781).
Secondary outcomes
Both EG and CG experienced significant improve-
ments in exercise capacity, muscle strength and
HRQOL during the study (p  0.002 – except for
SGRQ symptoms score, p ¼ 0.051), with no
between-group differences (0.148  p  0.987).
Self-efficacy remained constant throughout the study
in both groups (p ¼ 0.899, Table 3).
Discussion
This was the first randomised controlled trial that
evaluated the impact of a PA-focused behavioural
intervention comprising a Health contract and ped-
ometer feedback on PA levels of patients with COPD
during and after PR. The addition of this novel
approach to PR was effective in improving patients’
PA levels at 3 months, which remained improved
after follow-up support. Nevertheless, it did not pro-
duce further improvements in exercise capacity, mus-
cle strength or HRQOL.
The addition of the PA-focused behavioural inter-
vention to PR led to significant PA improvements in
the EG, which remained improved after follow-up
support. Findings suggest that this intervention is fea-
sible and enhances patients’ PA levels. A previous
study implementing a PA-focused intervention with
goal setting and pedometer feedback during PR
found only modest (non-significant) improvements
in patients’ daily steps.12 Differences between studies
may be explained by the different duration of the PR
programme (9 weeks vs. 12 weeks) and professional
support (five 30-minute individual sessions vs.
weekly 20–30 minute group sessions). When that
intervention was implemented in a 3-month period,
significant results were observed albeit the improve-
ment was less pronounced than in the present study
(547 steps/day vs. 3278.6 steps/day, respectively).10
Disease severity and baseline PA levels may explain
in part these discrepancies. Nevertheless, the type of
PA-focused intervention may have also played a
role, as in the present study a formal commitment
was encouraged by the use of the Health contract.
This technique has been applied with varied
degrees of success in interventions conducted with
other populations and health behaviours.18,35,36 It
has advantages over verbal communication alone,
since formal commitment enhances the individ-
ual–clinician relationship and stimulates the active
participation of the individual in identifying an
achievable health goal and creating a behaviour
change plan.37
The costs associated with the addition of the
PA-focused behavioural intervention to PR were rela-
tively small and related to the purchase of pedometers
and printed material (Health contract and calendar),
the telephone calls and the time needed by the phy-
siotherapist to provide support (approximately 20–
30 minute/session). Thus, this intervention can be
implemented in various healthcare settings without
Table 1. Characteristics of participants from both groups
(n ¼ 32).a
EG (n ¼ 16)
CG
(n ¼ 16) p
Age (years) 68.8+ 8.2 64.1 + 8.2 0.121
Sex (male), n (%) 13 (81.2) 14 (87.5) 0.626
Current occupation, n (%)
Retired 14 (87.5) 11 (68.8) 0.303
Employed 2 (12.5) 2 (12.5)
Unemployed 0 3 (18.8)
BMI (kg m2) 29.3+ 3.6 29.6 + 6.3 0.855
mMRC, M[IQR] 1.5 [1.0–2.0] 2.0 [1.0–2.5] 0.423
FEV1 (L) 1.9+ 0.8 2.0 + 0.7 0.699
FEV1 (% predicted) 65.5+ 21.1 68.4 + 19.7 0.697
GOLD grade, n (%)
Mild 6 (37.5) 6 (37.5) 0.623
Moderate 4 (25.0) 6 (37.5)
Severe to very
severe
6 (37.5) 4 (25.0)
Exacerbation risk, n (%)
A 5 (31.2) 5 (31.2) 0.776
B 4 (25.0) 6 (37.5)
C 3 (18.1) 1 (6.2)
D 4 (25.0) 4 (25.0)
BMI: body mass index; CG, control group; EG, experimental
group; FVC: forced vital capacity; FEV1: forced expiratory volume
in one second; GOLD: Global Initiative for Chronic Obstructive
Lung Disease; IQR, interquartile range; M: median; mMRC: Mod-
ified British Medical Research Council dyspnoea scale.
aData are presented as mean+ standard deviation, unless other-
wise indicated.
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Figure 2. PA levels of participants in the EG () and CG (!) at baseline, 3 and 6 months. Data are presented as mean and
standard error of the mean. Significant differences between groups in each time point are identified with an *. (a) Time in
MVPA. (b) Time in MVPA according to the international recommendations (i.e., 30 minutes of MVPA either continuous
or in blocks of10 minutes). (c) Time in total PA. (d) Number of daily steps. CG: control group; EG: experimental group;
MVPA: moderate-to-vigorous physical activity; PA: physical activity.
Table 2. Daily PA levels of participants in the EG (n ¼ 13) and CG (n ¼ 13) groups at baseline, 3 months and 6 months.a
Baseline 3 months 6 months pb η2partialc
Observed
powerd
Overall MVPA (min/day) EG 32.2 + 15.4 57.8 + 32.8 51.6 + 29.4 0.030e 0.21 0.89
CG 26.6 + 14.6 26.7 + 19.6 28.0 + 26.0
Recommended MVPA
(min/day)
EG 5.2 + 7.5 23.3 + 28.6 20.3 + 24.2 0.012e 0.17 0.78
CG 5.3 + 8.2 4.3 + 7.3 3.8 + 7.4
Total PA (min/day) EG 235.4 + 44.6 279.5 + 74.0 269.3 + 61.5 0.047e 0.12 0.59
CG 208.4 + 78.9 212.0 + 53.9 202.9 + 82.5
Steps (number/day) EG 7161.5 + 1708.1 10,440.0 + 4012.9 9747.9 + 3511.8 0.001e 0.27 0.96
CG 6617.1 + 2914.2 6430.0 + 2613.1 6481.3 + 3454.4
SA (min/day) EG 600.2 + 66.1 536.4 + 86.6 578.8 + 102.8 0.031e 0.14 0.66
CG 611.7 + 77.5 625.9 + 93.3 566.8 + 116.5
CG: control group; EG: experimental group; MVPA: moderate-to-vigorous physical activity; PA: physical activity; SA: sedentary
activities.
aData are presented as mean + standard deviation.
bp of time  group interaction.
cη2partial of time  group interaction.
dObserved power of time  group interaction.
eSignificant differences.
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the need for significant additional costs or human
resources. Further research is needed to study the
cost-effectiveness of this PA-focused behavioural
intervention.
Despite the PA improvements found in the EG,
there were no significant between-group differences
in exercise capacity, muscle strength and HRQOL,
similar to a previous study.10 Therefore, the hypoth-
esis that a more active lifestyle after the intervention
translates into improved health-related measures
could not be shown. One possible explanation is that
PA improvements may not have been enough to pro-
mote changes in patients’ daily life, as the minimum
clinically important difference of PA has not been
established in COPD.9 Other health-related measures
that were not explored in this study but have been
related to patients’ PA (e.g., exacerbations)38,39 may
have improved as a result of the intervention. This
should be explored in further research. The fact that
patients receiving the PR programme alone did not
improve their PA levels despite having similar exer-
cise capacity levels to those in the EG also supports
the idea that low PA levels, as frequently found in
patients with COPD, have a strong behavioural com-
ponent. This means that some patients may opt to
limit their PA levels rather than be restricted by their
symptoms or impairments.4
No significant differences were found for self-
efficacy over time in either group. Since self-
efficacy is the main construct of the SCT,16 it was
expected that a SCT-based behavioural intervention
would improve patients’ self-efficacy. However, stud-
ies conducted in COPD have shown conflicting
results regarding the relationship between PA and
self-efficacy,40–42 which may in part explain the
non-significant findings obtained in this study. These
findings may also be attributable to the use of a global
self-efficacy scale instead of a specific scale to
assess PA behaviour, given that self-efficacy is a
task-specific domain.43 Future research should apply
a PA self-efficacy scale.
Limitations
Findings from the present study must be interpreted in
light of the limitations. First, this was a small-scale
trial, therefore, the generalisability of the results to
clinical practice is limited. Nevertheless, the sample
size calculation and the large effect sizes found for
PA levels added strength to the results. Second,
patients had high functioning levels at baseline (mean
baseline step counts 6600–7200 steps/day, mean base-
line 6-mintute walking distance 493.8–476.2 m).
Future research is warranted to explore whether
Table 3. Outcome measures of patients of the EG (n ¼ 13) and CG (n ¼ 13).a
Baseline 3 months 6 months pb pc η2partiald
Observed
powere
6MWD (m) EG 493.8+ 63.0 547.9+ 47.9 540.4+ 31.1 0.962 <0.001f 0.53 0.99
CG 476.2+ 54.9 529.7+ 57.2 519.4+ 50.8
Quadriceps muscle strength (kg) EG 37.0+ 7.4 47.2+ 11.4 43.7 + 11.6 0.148 <0.001f 0.68 0.99
CG 40.7+ 8.0 51.0+ 10.8 43.8 + 8.2
SGRQ Global score EG 31.5+ 15.7 24.0+ 13.6 23.1 + 10.3 0.987 <0.001f 0.41 0.99
CG 34.9+ 14.7 26.9+ 15.2 26.2 + 15.3
SGRQ symptoms score EG 40.2+ 23.0 32.1+ 18.4 27.2 + 16.9 0.773 0.051 0.13 0.58
CG 41.2+ 22.7 35.9+ 21.6 34.0 + 26.3
SGRQ activities score EG 48.7+ 20.2 38.2+ 20.4 41.9 + 17.3 0.882 0.002f 0.25 0.92
CG 49.2+ 16.7 38.8+ 22.2 40.0 + 17.3
SGRQ impact score EG 18.4+ 13.2 13.1+ 11.6 10.8 + 7.8 0.833 <0.001f 0.36 0.99
CG 24.8+ 13.8 17.5+ 12.8 15.7 + 14.0
Self-efficacy EG 77.0+ 12.0 75.3+ 12.7 79.5 + 11.4 0.068 0.899 0.05 0.07
CG 82.4+ 10.4 85.7+ 11.1 79.6 + 13.0
CG: control group; EG: experimental group; SGRQ: St. George’s Respiratory Questionnaire; 6MWD: six-minute walking distance.
aData are presented as mean + standard deviation.
bp of time  group interaction.
cp of time.
dη2partial of time.
eObserved power of time.
fSignificant differences.
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patients with lower performance levels present similar
results after the intervention. Third, the PA-focused
behavioural intervention comprised asking patients
to walk 800 additional daily steps; however, not all
patients achieved the step target throughout the dura-
tion of the study (data not shown). Therefore, future
research should define the step-count goals according
to each patient’s performance, for example, by
increasing a percentage of the total steps achieved.
Fourth, all measures were administrated in a face-
to-face interview conducted by the same researchers
who implemented the intervention. Thus, assessor
blinding was not possible. Fifth, the short- and long-
term effects of the intervention were not studied,
therefore the sustainability of the results could not
be determined. Finally, both groups received the PR
during the same timeframe and hence seasonal varia-
tions were not taken into account, although they may
influence PA.26
Conclusions
A PA-focused behavioural intervention during and
after PR may improve patients’ PA levels. Further
research with larger samples and follow-up assess-
ments is warranted to support these preliminary find-
ings and assess the short- and long-term impact of this
intervention in COPD.
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